Give clinical trials data of probiotics for gastrointestiopnal disorders of patietns treated with GLP-1 agonists
Bottom line
The provided literature does not contain clinical trial data testing probiotics for gastrointestinal (GI) disorders in patients treated with GLP-1 receptor agonists or dual GIP/GLP-1 agonists. Therefore, no evidence-based claims can be made from the supplied text about probiotic efficacy, optimal strains, dosing, duration, or safety specifically for GLP-1–associated GI symptoms such as nausea, vomiting, constipation, diarrhea, bloating, delayed gastric emptying, or abdominal discomfort.
What the supplied evidence does provide is:
1. A randomized clinical trial involving liraglutide, a GLP-1 receptor agonist, in patients with bile acid diarrhea, including serum/fecal bile acid and fecal microbiota analyses; and
2. A narrative review of tirzepatide, a dual GIP/GLP-1 receptor agonist, summarizing multi-organ metabolic effects and preclinical effects on gut microbiota and intestinal barrier function.
Thus, the most accurate scientific answer is that clinical probiotic-trial evidence in GLP-1–treated patients is absent from the provided text, but relevant GLP-1/microbiota/GI data can be summarized.
1. Direct evidence for probiotics in GLP-1–treated patients
1.1 No probiotic intervention trials identified in the supplied text
Neither of the two supplied sources reports a clinical trial in which probiotics were administered to patients receiving GLP-1 receptor agonists or tirzepatide. There are no data on:
- Probiotic strains, e.g., Lactobacillus, Bifidobacterium, Saccharomyces, or multi-strain formulations
- Dose, colony-forming units, or treatment duration
- Effects on GLP-1–associated GI adverse events
- Outcomes such as nausea severity, vomiting frequency, constipation, diarrhea, gastric emptying, bloating, treatment discontinuation, or quality of life
- Safety outcomes of probiotics in this population
- Comparative efficacy versus placebo or standard care
Accordingly, the available evidence is insufficient to recommend probiotics specifically for GI disorders in patients treated with GLP-1 agonists on the basis of these sources alone.
2. Relevant clinical trial evidence: liraglutide in bile acid diarrhea
2.1 Trial design and population
The most directly relevant clinical study is a randomized, double-blind, double-dummy trial comparing liraglutide with colesevelam in patients with bile acid diarrhea (Ellegaard, 2024). Liraglutide is a GLP-1 receptor agonist, whereas colesevelam is a bile acid sequestrant.
The study included two active-treatment groups:
- Colesevelam: 1,875 mg orally twice daily, n = 26
- Liraglutide: subcutaneous treatment uptitrated weekly by 0.6 mg from 0.6 mg to 1.8 mg daily, n = 26
The total analyzed population described in the extract was therefore 52 patients. Participants had idiopathic or postcholecystectomy bile acid diarrhea verified by the 75-selenium-homotaurocholic acid test. Samples were assessed at baseline, 3 weeks, and 6 weeks (Ellegaard, 2024).
2.2 Outcomes measured
The trial evaluated:
- Serum bile acid species
- Fecal bile acid species
- Fecal microbiota composition using 16S rRNA gene amplicon sequencing
- Changes over time at baseline, week 3, and week 6
Importantly, this was not a probiotic trial. However, it is relevant because it investigated whether liraglutide altered bile acid metabolism and gut microbiota in a GI disorder population.
2.3 Main bile acid findings
Colesevelam and liraglutide had clearly different biological effects.
Colesevelam:
- Increased fecal concentrations of all bile acid species
- Decreased serum concentrations of secondary bile acids
- Mechanistically, this is consistent with colesevelam binding excess diarrhea-causing bile acids in the colon and promoting fecal bile acid excretion (Ellegaard, 2024)
Liraglutide:
- Produced a small increase in serum unconjugated bile acid concentrations
- Did not affect fecal bile acid concentrations
- The authors suggested that liraglutide may act by slowing small intestinal transit, allowing more time for passive bile acid absorption (Ellegaard, 2024)
This is clinically relevant because GLP-1 receptor agonists are known to slow gastrointestinal transit, and in bile acid diarrhea this effect may reduce diarrheal symptoms through mechanisms distinct from bile acid binding.
2.4 Microbiota findings
Despite the GI condition and the use of a GLP-1 receptor agonist, the trial found:
- No changes in fecal microbiota composition with liraglutide
- No changes in fecal microbiota composition with colesevelam
Microbiota was assessed by 16S rRNA gene amplicon sequencing at the same time points as bile acids: baseline, 3 weeks, and 6 weeks (Ellegaard, 2024).
This finding is important for the probiotic question. If liraglutide improved bile acid diarrhea symptoms, the supplied abstract suggests that this effect was not mediated by detectable shifts in fecal microbiota composition over 6 weeks. Therefore, the rationale for probiotics as an adjunct to liraglutide-treated GI symptoms remains unproven in this dataset.
2.5 Statistical reliability
The supplied text does not provide p-values, confidence intervals, effect sizes, responder rates, stool-frequency changes, or symptom-score differences. Therefore, the magnitude and statistical certainty of the clinical symptom benefit cannot be independently assessed from the provided material. The study’s strengths include its randomized, double-blind, double-dummy design and active comparator, but the extract provides limited quantitative outcome data.
3. Tirzepatide, gut microbiota, and gastrointestinal mechanisms
3.1 Tirzepatide as a dual GIP/GLP-1 agonist
The second source is a narrative review of tirzepatide, a dual agonist of the glucose-dependent insulinotropic peptide receptor and GLP-1 receptor (Irshad, 2026). Tirzepatide is described as a multi-organ metabolic therapy affecting pancreatic β-cells, adipose tissue, liver, gastrointestinal tract, cardiovascular system, kidneys, brain, and gut microbiota.
Its major physiological effects include:
- Increased insulin levels
- Decreased glucagon levels
- Slowed gastric emptying
- Increased satiety/fullness
- Significant weight loss
- Improved glycemic control
- Improved lipid profiles
- Reduced hepatic steatosis
- Potential cardio-renal protection (Irshad, 2026)
3.2 Clinical trial programs: SURPASS and SURMOUNT
The review states that the SURPASS and SURMOUNT clinical trial programs demonstrated improved glycemic control and weight loss with tirzepatide compared with current treatments (Irshad, 2026). However, the supplied text does not provide trial-specific numerical results such as body-weight change, HbA1c reduction, GI adverse-event rates, discontinuation rates, or confidence intervals.
Therefore, while tirzepatide has strong clinical-trial evidence for metabolic outcomes, the provided text does not provide clinical trial data on probiotic treatment of tirzepatide-associated GI symptoms.
3.3 Preclinical microbiota effects
The review reports that preclinical studies showed tirzepatide may alter gut microbiota composition, specifically:
- Increased Bacteroidetes
- Decreased Firmicutes
- Enhanced intestinal barrier integrity (Irshad, 2026)
These findings may be mechanistically interesting because microbiota composition and intestinal barrier function are implicated in metabolic inflammation and gut-liver signaling. However, these are preclinical observations, not probiotic clinical trial outcomes. They do not establish that probiotic supplementation improves GLP-1–related GI tolerability or metabolic efficacy.
4. Interpretation for the clinical question
4.1 What can be concluded
From the supplied evidence:
- There is clinical trial evidence that liraglutide changes serum bile acid profiles in patients with bile acid diarrhea and differs mechanistically from colesevelam (Ellegaard, 2024).
- In that trial, neither liraglutide nor colesevelam changed fecal microbiota composition over 6 weeks (Ellegaard, 2024).
- Tirzepatide has documented multi-organ metabolic effects and may alter microbiota composition in preclinical studies, but clinical probiotic-intervention data are not provided (Irshad, 2026).
4.2 What cannot be concluded
The supplied literature does not support conclusions about:
- Whether probiotics reduce nausea, vomiting, constipation, or diarrhea in GLP-1–treated patients
- Whether probiotics reduce discontinuation of GLP-1 agonists due to GI intolerance
- Whether probiotics modify gastric emptying delay caused by GLP-1 therapies
- Whether probiotics enhance weight loss or glycemic response to GLP-1 agonists
- Which probiotic formulation, if any, is best suited for GLP-1 users
5. Evidence gap and future trial needs
A properly designed clinical trial to answer the user’s question would need to randomize GLP-1–treated patients with GI symptoms to probiotic versus placebo. Key endpoints should include validated nausea/vomiting scores, stool frequency, Bristol Stool Form Scale, constipation severity, bloating scores, treatment discontinuation, microbiome sequencing, bile acid profiling, and metabolic outcomes such as HbA1c and body weight. Stratification by agent—semaglutide, liraglutide, dulaglutide, or tirzepatide—would be important because GI physiology and adverse-event profiles may differ.
In summary, based strictly on the provided sources, there are no clinical trial data demonstrating probiotic efficacy for gastrointestinal disorders in patients treated with GLP-1 agonists. The available evidence instead shows that GLP-1–based therapies can influence GI transit, bile acid physiology, and possibly gut microbial ecology, but probiotic therapy remains an untested intervention in this specific clinical setting.